Significantly greater improvement in adjusted mean HDRS17 total score from baseline to week 8 was observed for desvenlafaxine 50 mg ( -11.28 ; P = .006 ) and desvenlafaxine 100 mg ( -11.67 ; P < .001 ) compared with placebo ( -9.71 ) , with adjustment for multiplicity .